NO743394L - - Google Patents

Info

Publication number: NO743394L
Authority: NO; Norway
Prior art keywords: glibenclamide; phenformin; salt; preparation according; hydrochloride
Prior art date: 1973-09-21

Application number

NO743394A

Other languages

English (en)

Norwegian (no)

Inventor

W Fuelberth

D Hiller

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1973-09-21

Filing date

1974-09-20

Publication date

1975-04-14

1974-09-20 Application filed by Hoechst Ag filed Critical Hoechst Ag

1975-04-14 Publication of NO743394L publication Critical patent/NO743394L/no

Links

229960004580 glibenclamide Drugs 0.000 claims description 27
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 27
238000002360 preparation method Methods 0.000 claims description 24
ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical class NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims description 18
238000004519 manufacturing process Methods 0.000 claims description 8
QMNAQPMXDMLOLD-UHFFFAOYSA-N 6-methyl-4-oxo-5,6-dihydrothieno[2,3-b]thiopyran-2-sulfonamide Chemical compound S1C(C)CC(=O)C2=C1SC(S(N)(=O)=O)=C2 QMNAQPMXDMLOLD-UHFFFAOYSA-N 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
238000000034 method Methods 0.000 claims description 6
229960001753 phenformin hydrochloride Drugs 0.000 claims description 6
206010012601 diabetes mellitus Diseases 0.000 claims description 5
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
238000002560 therapeutic procedure Methods 0.000 claims description 4
239000011248 coating agent Substances 0.000 claims description 3
238000000576 coating method Methods 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
230000002496 gastric effect Effects 0.000 claims description 3
239000011159 matrix material Substances 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
YSUCWSWKRIOILX-UHFFFAOYSA-N 1-(diaminomethylidene)-2-(2-phenylethyl)guanidine;hydrochloride Chemical compound Cl.NC(N)=NC(N)=NCCC1=CC=CC=C1 YSUCWSWKRIOILX-UHFFFAOYSA-N 0.000 claims description 2
239000000969 carrier Substances 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
239000007787 solid Substances 0.000 claims 2
239000008187 granular material Substances 0.000 description 15
229960003243 phenformin Drugs 0.000 description 12
239000000203 mixture Substances 0.000 description 11
239000001993 wax Substances 0.000 description 7
229920002261 Corn starch Polymers 0.000 description 6
230000008901 benefit Effects 0.000 description 6
239000008120 corn starch Substances 0.000 description 6
229940099112 cornstarch Drugs 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
229940123208 Biguanide Drugs 0.000 description 4
239000013543 active substance Substances 0.000 description 4
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
229940100389 Sulfonylurea Drugs 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
238000004898 kneading Methods 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
238000009097 single-agent therapy Methods 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
150000004283 biguanides Chemical class 0.000 description 1
238000007664 blowing Methods 0.000 description 1
229960004111 buformin Drugs 0.000 description 1
XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
239000001175 calcium sulphate Substances 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229960003105 metformin Drugs 0.000 description 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO743394A 1973-09-21 1974-09-20 NO743394L (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19732347531 DE2347531A1 (de)	1973-09-21	1973-09-21	Arzneizubereitungen zur oralen diabetes-behandlung

Publications (1)

Publication Number	Publication Date
NO743394L true NO743394L (fr)	1975-04-14

Family

ID=5893251

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO743394A NO743394L (fr)	1973-09-21	1974-09-20

Country Status (12)

Country	Link
JP (1)	JPS5053521A (fr)
AU (1)	AU7349374A (fr)
BE (1)	BE820222A (fr)
DE (1)	DE2347531A1 (fr)
DK (1)	DK496774A (fr)
FI (1)	FI274174A (fr)
FR (1)	FR2244481A1 (fr)
IL (1)	IL45690A0 (fr)
NL (1)	NL7412254A (fr)
NO (1)	NO743394L (fr)
SE (1)	SE7411852L (fr)
ZA (1)	ZA745981B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS61260013A (ja) *	1985-05-14	1986-11-18	Katsumi Takada	三部分からなる多層錠
CA2217233A1 (fr) *	1995-04-03	1996-10-10	Chugai Seiyaku Kabushiki Kaisha	Composition pharmaceutique renfermant du sucralfate
AR030920A1 (es) *	1999-11-16	2003-09-03	Smithkline Beecham Plc	Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
FR2816841B1 (fr) *	2000-11-22	2004-02-06	Lipha	Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation
MXPA03006217A (es) *	2001-01-12	2004-10-15	Sun Pharmaceutical Ind Ltd	Sistema de administracion espaciada de farmacos.
ITFI20010230A1 (it) *	2001-11-29	2003-05-29	Menarini Int Operations Lu Sa	Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii

1973
- 1973-09-21 DE DE19732347531 patent/DE2347531A1/de active Pending
1974
- 1974-09-16 NL NL7412254A patent/NL7412254A/xx unknown
- 1974-09-19 AU AU73493/74A patent/AU7349374A/en not_active Expired
- 1974-09-19 FI FI2741/74A patent/FI274174A/fi unknown
- 1974-09-20 NO NO743394A patent/NO743394L/no unknown
- 1974-09-20 DK DK496774A patent/DK496774A/da unknown
- 1974-09-20 SE SE7411852A patent/SE7411852L/ not_active Application Discontinuation
- 1974-09-20 ZA ZA00745981A patent/ZA745981B/xx unknown
- 1974-09-21 JP JP49108328A patent/JPS5053521A/ja active Pending
- 1974-09-22 IL IL45690A patent/IL45690A0/xx unknown
- 1974-09-23 BE BE148792A patent/BE820222A/fr unknown
- 1974-09-23 FR FR7432021A patent/FR2244481A1/fr not_active Withdrawn

Also Published As

Publication number	Publication date
BE820222A (fr)	1975-03-24
NL7412254A (nl)	1975-03-25
ZA745981B (en)	1975-10-29
JPS5053521A (fr)	1975-05-12
IL45690A0 (en)	1974-11-29
FR2244481A1 (en)	1975-04-18
DK496774A (fr)	1975-05-26
AU7349374A (en)	1976-03-25
DE2347531A1 (de)	1975-04-30
FI274174A (fr)	1975-03-22
SE7411852L (fr)	1975-03-24

Publication	Publication Date	Title
CN101273981B (zh)	2011-01-26	抗糖尿病制剂以及制药用途
DE69627883T2 (de)	2004-05-19	Zusammensetzung von glibenclamid und metformine zur behandlung von diabetes mellitis typ ii
CN1146427C (zh)	2004-04-21	含有二甲双胍和格列本脲的固体口服剂型
CN101897696B (zh)	2014-06-18	降糖药物组合物及其用途
US7183321B2 (en)	2007-02-27	Antidiabetic formulation and method
RU2201272C2 (ru)	2003-03-27	Применение ингибиторов желудочно-кишечной липазы
JP2003081870A (ja)	2003-03-19	甲状腺ホルモンの製薬化
CN104586834A (zh)	2015-05-06	一种艾帕列净和二甲双胍的药物组合物及其制备方法
CN104884051A (zh)	2015-09-02	包含吉格列汀和二甲双胍的组合药物及其制备方法
NO743394L (fr)	1975-04-14
CN101990427A (zh)	2011-03-23	米格列奈及二甲双胍的复合制剂及其制造方法
JPH0840906A (ja)	1996-02-13	過血糖症を治療するための薬剤学的製剤
TW586926B (en)	2004-05-11	A pharmaceutical composition for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal
CN104739835A (zh)	2015-07-01	一种治疗糖尿病的新型药物组合物
CN112972410A (zh)	2021-06-18	一种西那卡塞药物组合物片剂及其医药用途
CN101897698A (zh)	2010-12-01	含有维格列汀和b族维生素的降糖药物组合物及其用途
CN109771424B (zh)	2021-03-16	一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用
CN111084777A (zh)	2020-05-01	一种吡贝地尔、左旋多巴与苄丝肼复方缓释三层片剂及其制备方法
CN112972480A (zh)	2021-06-18	一种含牛磺熊去氧胆酸、苯丁酸钠的复方散剂/颗粒剂、制备方法、用途以及其药物组合物
EP0005733B1 (fr)	1988-07-20	Compositions pharmaceutiques pour application dans le traitement de la néphropathie diabétique et procédé pour leur préparation
CN104840480B (zh)	2020-10-13	二甲双胍/叶酸/维生素b12药物组合物的新用途
JP2004513962A (ja)	2004-05-13	抗糖尿病作用を有する新規な薬剤組成物およびその製剤方法
CN115245495B (zh)	2022-12-23	一种西格列汀二甲双胍片及其制备方法
CN107281200B (zh)	2018-05-29	一种含1,6-二磷酸果糖的复方固体制剂及其制备方法
RU2304439C1 (ru)	2007-08-20	Лекарственное средство и способ лечения сахарного диабета